Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Warrant (NQ: APLMW )

0.0154 +0.0053 (+52.48%)
Streaming Delayed Price Updated: 3:10 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apollomics Inc. - Warrant

< Previous 1 2 Next >
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with... 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR... 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
From Apollomics Inc.
Via GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
From Apollomics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.